专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060040999A1 CETP inhibitors 有权
标题翻译： CETP抑制剂
公开(公告)号：US20060040999A1
公开(公告)日：2006-02-23
申请号：US11173295
申请日：2005-07-01
申请人： Amjad Ali , Joann Napolitano , Qiaolin Deng , Zhijian Lu , Peter Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi , Cameron Smith , Julianne Hunt , Adrian Dowst , Yi-Heng Chen , Hong Li
发明人： Amjad Ali , Joann Napolitano , Qiaolin Deng , Zhijian Lu , Peter Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi , Cameron Smith , Julianne Hunt , Adrian Dowst , Yi-Heng Chen , Hong Li
IPC分类号： A61K31/421 , C07D263/16
CPC分类号： C07F7/10 , A61K31/4015 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07D207/26 , C07D207/27 , C07D233/32 , C07D233/38 , C07D233/50 , C07D233/52 , C07D263/04 , C07D263/20 , C07D263/22 , C07D263/24 , C07D263/26 , C07D285/06 , C07D285/10 , C07D401/04 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/04 , C07D417/10
摘要： Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
摘要翻译：具有式I结构的化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于升高HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。在式I化合物中，B或 R 2是具有邻芳基，杂环，苯并杂环或苯并环烷基取代基的苯基，并且在5元环上的另一个位置具有直接连接的芳族，杂环，环烷基，苯并杂环或苯并环烷基取代基通过-CH 2 - 2连接到环上或连接到环上。

2. 发明申请

US20070225365A1 Cetp Inhibitors 有权
标题翻译： Cetp抑制剂
公开(公告)号：US20070225365A1
公开(公告)日：2007-09-27
申请号：US11578694
申请日：2005-04-08
申请人： Amjad Ali , Joann Bohn , Qiaolin Deng , Zhijian Lu , Peter Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi
发明人： Amjad Ali , Joann Bohn , Qiaolin Deng , Zhijian Lu , Peter Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi
IPC分类号： A61K31/216 , C07C69/612
CPC分类号： C07C271/20 , C07C233/18 , C07C271/16 , C07C271/22 , C07C279/08 , C07C311/04 , C07C311/08 , C07C317/32 , C07D209/08 , C07D213/40 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/89 , C07D215/12 , C07D215/26 , C07D217/02 , C07D217/14 , C07D261/08 , C07D271/06 , C07D307/52 , C07D307/79 , C07D333/20 , C07D333/22 , C07D333/28
摘要： Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
摘要翻译：式I化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于培养HDL-胆固醇，降低LDL-胆固醇，以及治疗或预防动脉粥样硬化。在式1化合物中，A 1和A 2各自为芳环，5-6元杂环，稠合至杂环的芳环，与杂环稠合的苯环或环烷基环。

3. 发明授权

US08193365B2 CETP inhibitors 有权
标题翻译： CETP抑制剂
公开(公告)号：US08193365B2
公开(公告)日：2012-06-05
申请号：US12815146
申请日：2010-06-14
申请人： Amjad Ali , Joann Bohn , Qiaolin Deng , Zhijian Lu , Peter J. Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi
发明人： Amjad Ali , Joann Bohn , Qiaolin Deng , Zhijian Lu , Peter J. Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi
IPC分类号： C07D261/02 , C07D209/04 , C07D307/93 , A01N57/26 , A01N57/00
CPC分类号： A61K31/343 , A61K31/381 , A61K31/404 , A61K31/42 , A61K31/44 , A61K31/4412 , A61K31/455 , A61K31/47 , A61K31/472 , A61K38/00 , A61K45/06 , C07C233/16 , C07C271/16 , C07C271/20 , C07C271/22 , C07C275/32 , C07C311/04 , C07C311/08 , C07C317/32 , C07D209/08 , C07D213/54 , C07D215/12 , C07D217/02 , C07D261/08 , C07D271/10 , C07D307/14 , C07D307/79 , C07D333/20 , C07D333/22 , C07D333/28 , A61K2300/00
摘要： Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
摘要翻译：式I化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于培养HDL-胆固醇，降低LDL-胆固醇，以及治疗或预防动脉粥样硬化。在式1化合物中，A1和A2各自为芳环，5-6元杂环，稠合于杂环的芳环，稠合于杂环的苯环或环烷基环。

4. 发明申请

US20080076795A1 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators 失效
标题翻译： 1H-苯并[F]吲唑-5-YL衍生物作为选择性糖皮质激素受体调节剂
公开(公告)号：US20080076795A1
公开(公告)日：2008-03-27
申请号：US11904186
申请日：2007-09-26
申请人： Amjad Ali , James Balkovec , Donald Graham , Christopher Thompson , Nazia Quraishi
发明人： Amjad Ali , James Balkovec , Donald Graham , Christopher Thompson , Nazia Quraishi
IPC分类号： A61K31/416 , A61K31/4184 , A61K31/427 , A61K31/428 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61P29/00 , A61P37/00 , C07D231/54 , C07D401/02 , C07D403/02 , C07D405/02 , C07D409/02 , C07D417/02
CPC分类号： C07D417/06 , C07D231/54 , C07D401/06 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/10 , C07D409/06
摘要： The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
摘要翻译：本发明包括式I化合物或其药学上可接受的盐或水合物，其可用作用于治疗多种自身免疫性和炎性疾病或病症的选择性糖皮质激素受体配体。还包括药物组合物和使用方法。

5. 发明申请

US20050256315A1 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators 失效
标题翻译： 1h-苯并{f}吲唑-5-基衍生物作为选择性糖皮质激素受体调节剂
公开(公告)号：US20050256315A1
公开(公告)日：2005-11-17
申请号：US10508897
申请日：2003-04-08
申请人： Amjad Ali , James Balkovec , Donald Graham , Christopher Thompson , Nazia Quraishi
发明人： Amjad Ali , James Balkovec , Donald Graham , Christopher Thompson , Nazia Quraishi
IPC分类号： A61K31/416 , A61K31/4184 , A61K31/427 , A61K31/428 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61P1/04 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/10 , A61P3/14 , A61P7/04 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/14 , A61P19/08 , A61P21/00 , A61P21/02 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P27/16 , A61P29/00 , A61P31/04 , A61P31/18 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07D231/54 , C07D231/56 , C07D249/16 , C07D401/06 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/10 , C07D409/06 , C07D417/06
CPC分类号： C07D417/06 , C07D231/54 , C07D401/06 , C07D403/04 , C07D403/06 , C07D403/10 , C07D405/06 , C07D405/10 , C07D409/06
摘要： The present invention encompasses compounds of Formula I: (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharamaceutical compositions and methods of use are also included.
摘要翻译：本发明包括式I化合物：（I）或其药学上可接受的盐或水合物，其可用作治疗各种自身免疫性和炎性疾病或病症的选择性糖皮质激素受体配体。还包括制药组合物和使用方法。

6. 发明申请

US20060074120A1 Selective non-steroidal glucocorticoid receptor modulators 失效
标题翻译：选择性非甾体糖皮质激素受体调节剂
公开(公告)号：US20060074120A1
公开(公告)日：2006-04-06
申请号：US10544899
申请日：2004-02-20
申请人： Amjad Ali , Richard Beresis , Steven Colletti , Donald Graham , James Tata , Christopher Thompson
发明人： Amjad Ali , Richard Beresis , Steven Colletti , Donald Graham , James Tata , Christopher Thompson
IPC分类号： C07D231/54 , A61K31/4162
CPC分类号： C07D409/12 , C07D231/54 , C07D401/12 , C07D403/06 , C07D403/12 , C07D409/04
摘要： The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as novel non-steroidal selective glucocorticoid receptor modulators for treating a variety of autoimmune and inflammatory diseases or conditions, and possess advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity and/or metabolism. Pharmaceutical compositions and methods of use are also included.
摘要翻译：本发明包括式（I）化合物或其药学上可接受的盐或水合物，其可用作新型非甾体选择性糖皮质激素受体调节剂，用于治疗多种自身免疫性和炎性疾病或病症，并且具有超过甾族糖皮质激素配体的优点，尊重不良的副作用，功效，毒性和/或代谢。还包括药物组合物和使用方法。

7. 发明申请

US20110224839A1 Power Point Tracking 审中-公开
标题翻译：功率点跟踪
公开(公告)号：US20110224839A1
公开(公告)日：2011-09-15
申请号：US12722163
申请日：2010-03-11
申请人： Christopher Thompson
发明人： Christopher Thompson
IPC分类号： G06F1/28 , H01L31/042 , G06G7/63
CPC分类号： H01L31/02021 , G05F1/67 , Y02E10/50
摘要： An maximum power point tracking unit used in a solar cell power system can find maximum power point more efficiently.
摘要翻译：在太阳能电池电力系统中使用的最大功率点跟踪单元可以更有效地找到最大功率点。

8. 发明申请

US20080134585A1 Compositions for polishing aluminum/copper and titanium in damascene structures 有权
标题翻译：用于在镶嵌结构中抛光铝/铜和钛的组合物
公开(公告)号：US20080134585A1
公开(公告)日：2008-06-12
申请号：US11634576
申请日：2006-12-06
申请人： Vlasta Brusic , Renjie Zhou , Paul Feeney , Christopher Thompson
发明人： Vlasta Brusic , Renjie Zhou , Paul Feeney , Christopher Thompson
IPC分类号： C09K3/14
CPC分类号： H01L21/3212 , C09G1/02 , C09K3/1409 , C09K3/1436 , C09K3/1463
摘要： The invention provides a chemical-mechanical polishing composition for polishing a substrate. The polishing composition comprises an oxidizing agent, calcium ion, an organic carboxylic acid, and water, wherein the polishing composition has a pH of about 1.5 to about 7. The invention further provides a method of chemically-mechanically polishing a substrate with the aforementioned polishing composition.
摘要翻译：本发明提供了一种用于抛光基材的化学机械抛光组合物。抛光组合物包含氧化剂，钙离子，有机羧酸和水，其中抛光组合物的pH为约1.5至约7.本发明还提供了用上述抛光对基材进行化学机械研磨的方法组成。

9. 发明申请

US20080035158A1 Apparatus and Methods for Treating Sleep Apnea 有权
标题翻译：用于治疗睡眠呼吸暂停的装置和方法
公开(公告)号：US20080035158A1
公开(公告)日：2008-02-14
申请号：US11774528
申请日：2007-07-06
申请人： D. Pflueger , Christopher Thompson
发明人： D. Pflueger , Christopher Thompson
IPC分类号： A62B7/00
CPC分类号： A61F5/566 , A61F2/00 , A61F2/203 , A61F2/82 , A61F2002/046 , Y10S602/902
摘要： Apparatus and methods are provided for treating sleep apnea, snoring, and the like using an implant within an oropharyngeal region adjacent an anterior longitudinal ligament. The implant includes an endless loop defining a curved central region between first and second regions in a horizontal plane. The central region is vertically narrow relative to the first and second regions, and the first and second regions are compressible vertically to allow the first region to be directed through or behind the ligament adjacent the oropharyngeal region such that the central region is disposed within or behind the ligament. The first region is resiliently expandable after passing through or behind the ligament to contact tissue adjacent the oropharyngeal region. The first and second regions are compressible into a “C” shape within the horizontal plane, yet biased to expand and apply a force to dilate the tissue adjacent the oropharyngeal region.
摘要翻译：提供了使用邻近前纵韧带的口咽部区域内的植入物来治疗睡眠呼吸暂停，打鼾等的装置和方法。植入物包括在水平面中限定第一和第二区域之间的弯曲中心区域的无限循环。中心区域相对于第一和第二区域是垂直窄的，并且第一和第二区域是可垂直压缩的，以允许第一区域被引导通过毗邻口咽区域的韧带中或后面，使得中心区域位于或后面韧带。第一区域在通过或穿过韧带后可弹性膨胀以接触邻近口咽区域的组织。第一和第二区域在水平面内可压缩成“C”形，但是被偏压以膨胀并且施加力以扩张毗邻口咽部区域的组织。

10. 发明申请

US20070090094A1 CMP of copper/ruthenium substrates 有权
公开(公告)号：US20070090094A1
公开(公告)日：2007-04-26
申请号：US11259645
申请日：2005-10-26
申请人： Christopher Thompson , Vlasta Brusic , Renjie Zhou
发明人： Christopher Thompson , Vlasta Brusic , Renjie Zhou
IPC分类号： C03C15/00 , C23F1/00 , H01L21/302 , B44C1/22
CPC分类号： H01L21/3212 , C09G1/02 , C23F3/04
摘要： The invention provides a method of chemically-mechanically polishing a substrate. A substrate comprising ruthenium and copper is contacted with a chemical-mechanical polishing system comprising a polishing component, hydrogen peroxide, an organic acid, at least one heterocyclic compound comprising at least one nitrogen atom, and water. The polishing component is moved relative to the substrate, and at least a portion of the substrate is abraded to polish the substrate. The pH of the polishing system is about 6 to about 12, the ruthenium and copper are in electrical contact, and the difference between the open circuit potential of copper and the open circuit potential of ruthenium in the polishing system is about 50 mV or less.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式